Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SFDA Steps Up New Drug Approval For H1N1 Flu

This article was originally published in PharmAsia News

Executive Summary

China's State FDA has identified concrete measures against the influenza A (H1N1) virus. The agency will: (1) set up an expert panel in charge of H1N1 flu drug evaluation and approval to gear up for early R&D involvement and rapid approval of resultant drugs; (2) coordinate departments on new drug acceptance, examination and testing to prepare for special procedures of H1N1 flu drug approval; (3) pay close attention to R&D of Class-I new drugs of neuraminidase inhibitors; (4) survey the nation's flu drugs and medical devices by conducting on-site inspections of relevant pharmaceutical companies' production plans and capacities; and (5) demand drug administration departments enhance supervision of drug and medical device quality for H1N1 flu. (Click here for more - Chinese language

You may also be interested in...

Industry Delighted By ‘Fixed’ USMCA

Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.

NeuClone’s Trastuzumab Trial Succeeds

NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.

EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts